RT Journal Article
SR Electronic
T1 Non-pharmaceutical interventions and inoculation rate shape SARS-COV-2 vaccination campaign success
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.22.21252240
DO 10.1101/2021.02.22.21252240
A1 Galanti, Marta
A1 Pei, Sen
A1 Yamana, Teresa K.
A1 Angulo, Frederick J.
A1 Charos, Apostolos
A1 Khan, Farid
A1 Shea, Kimberly M.
A1 Swerdlow, David L.
A1 Shaman, Jeffrey
YR 2021
UL http://medrxiv.org/content/early/2021/02/25/2021.02.22.21252240.abstract
AB Nearly one year into the COVID-19 pandemic, the first SARS-COV-2 vaccines received emergency use authorization and vaccination campaigns began. A number of factors can reduce the averted burden of cases and deaths due to vaccination. Here, we use a dynamic model, parametrized with Bayesian inference methods, to assess the effects of non-pharmaceutical interventions, and vaccine administration and uptake rates on infections and deaths averted in the United States. We estimate that high compliance with non-pharmaceutical interventions could avert more than 60% of infections and 70% of deaths during the period of vaccine administration, and that increasing the vaccination rate from 5 to 11 million people per week could increase the averted burden by more than one third. These findings underscore the importance of maintaining non-pharmaceutical interventions and increasing vaccine administration rates.Competing Interest StatementFA, AC, FK, KS, and DS are employees of Pfizer and may hold stock or stock options. JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI. MG, SP and TKY have no competing interests.Funding StatementThis project was supported by Pfizer Vaccines, National Science Foundation grant DMS-2027369, and a gift from the Morris-Singer Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research is model-based made using publicly available data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInference data and model output are available on the Github repository https://github.com/shaman-lab. https://github.com/shaman-lab